PMID- 31603934
OWN - NLM
STAT- MEDLINE
DCOM- 20200313
LR  - 20200313
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 10
DP  - 2019
TI  - Clinical use of SAND battery to evaluate language in patients with Progressive 
      Supranuclear Palsy.
PG  - e0223621
LID - 10.1371/journal.pone.0223621 [doi]
LID - e0223621
AB  - BACKGROUND: Progressive Supranuclear Palsy (PSP) patients present language 
      disturbances in tasks like naming, repetition, reading, word comprehension and 
      semantic association compared to Parkinson's disease (PD) and healthy controls 
      (HC). OBJECTIVE: In the present study we sought to validate a Screening for 
      Aphasia in NeuroDegeneration (SAND) battery version specifically tailored on PSP 
      patients and to describe language impairment in relation to PSP disease phenotype 
      and cognitive status. METHODS AND RESULTS: Fifty-one PSP [23 with Richardson's 
      syndrome (PSP-RS), 10 with predominant parkinsonism (PSP-P) and 18 with the other 
      variant syndromes of PSP (vPSP)], 28 PD and 30 HC were enrolled in the present 
      study. By excluding the tasks with poor acceptability (i.e., writing and picture 
      description tasks) and increasing the items related to the remaining tasks, we 
      showed that the PSP-tailored SAND Global Score is an acceptable, consistent and 
      reliable tool to screen language disturbances in PSP. However, we failed to 
      detect major differences in language involvement according to disease phenotype. 
      Differently, we showed that patients with dementia present worse language 
      performances. CONCLUSIONS: Taking into account specific disease features, the 
      combination of the SAND subscores included in the PSP-tailored SAND better 
      represents language abilities in PSP. Furthermore, we showed that language 
      disturbances feature PSP patients irrespective of disease phenotype, but 
      parallels the deterioration of the global cognitive function.
FAU - Picillo, Marina
AU  - Picillo M
AUID- ORCID: 0000-0001-9025-137X
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
FAU - Cuoco, Sofia
AU  - Cuoco S
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
FAU - Carotenuto, Immacolata
AU  - Carotenuto I
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
FAU - Abate, Filomena
AU  - Abate F
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
FAU - Erro, Roberto
AU  - Erro R
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
FAU - Volpe, Giampiero
AU  - Volpe G
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
FAU - Pellecchia, Maria Teresa
AU  - Pellecchia MT
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
FAU - Catricala, Eleonora
AU  - Catricala E
AD  - University School for Advanced Studies IUSS Pavia, Pavia, Italy.
FAU - Cappa, Stefano
AU  - Cappa S
AD  - University School for Advanced Studies IUSS Pavia, Pavia, Italy.
AD  - IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
FAU - Barone, Paolo
AU  - Barone P
AD  - Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery 
      and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191011
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Aged
MH  - Cognition
MH  - Female
MH  - Humans
MH  - *Language
MH  - Male
MH  - *Neuropsychological Tests
MH  - Phenotype
MH  - Reproducibility of Results
MH  - Supranuclear Palsy, Progressive/*diagnosis
PMC - PMC6788681
COIS- PB received consultancies as a member of the advisory board for Zambon, Lundbeck, 
      UCB, Chiesi, Abbvie and Acorda. RE received consultancies from Zambon and 
      honoraria from TEVA. There are no patents, products in development or marketed 
      products associated with this research to declare. This does not alter our 
      adherence to PLOS ONE policies on sharing data and materials.
EDAT- 2019/10/12 06:00
MHDA- 2020/03/14 06:00
PMCR- 2019/10/11
CRDT- 2019/10/12 06:00
PHST- 2019/06/17 00:00 [received]
PHST- 2019/09/24 00:00 [accepted]
PHST- 2019/10/12 06:00 [entrez]
PHST- 2019/10/12 06:00 [pubmed]
PHST- 2020/03/14 06:00 [medline]
PHST- 2019/10/11 00:00 [pmc-release]
AID - PONE-D-19-17153 [pii]
AID - 10.1371/journal.pone.0223621 [doi]
PST - epublish
SO  - PLoS One. 2019 Oct 11;14(10):e0223621. doi: 10.1371/journal.pone.0223621. 
      eCollection 2019.